Neuromedin U Receptor 1 Deletion Leads to Impaired Immunotherapy Response and High Malignancy in Colorectal Cancer

Overview

Journal iScience

Publisher Cell Press

Date 2024 Jul 26

PMID 39055918

Authors

Yulai Zhou

Xiangyang Zhang

Yan Gao

Yinghui Peng

Ping Liu

Yihong Chen

Cao Guo

Gongping Deng

Yanhong Ouyang

Yan Zhang

Ying Han

Changjing Cai

Hong Shen

Le Gao

Shan Zeng

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) exhibits significant heterogeneity, impacting immunotherapy efficacy, particularly in immune desert subtypes. Neuromedin U receptor 1 (NMUR1) has been reported to perform a vital function in immunity and inflammation. Through comprehensive multi-omics analyses, we have systematically characterized NMUR1 across various tumors, assessing expression patterns, genetic alterations, prognostic significance, immune infiltration, and pathway associations at both the bulk sequencing and single-cell scales. Our findings demonstrate a positive correlation between NMUR1 and CD8 T cell infiltration, with elevated NMUR1 levels in CD8 T cells linked to improved immunotherapy outcomes in patients with CRC. Further, we have validated the NMUR1 expression signature in CRC cell lines and patient-derived tissues, revealing its interaction with key immune checkpoints, including lymphocyte activation gene 3 and cytotoxic T-lymphocyte-associated protein 4. Additionally, NMUR1 suppression enhances CRC cell proliferation and invasiveness. Our integrated analyses and experiments open new avenues for personalized immunotherapy strategies in CRC treatment.

References

Derakhshani A, Hashemzadeh S, Asadzadeh Z, Shadbad M, Rasibonab F, Safarpour H . Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. Cancers (Basel). 2021; 13(10). PMC: 8155910. DOI: 10.3390/cancers13102414. View

Peier A, Desai K, Hubert J, Du X, Yang L, Qian Y . Effects of peripherally administered neuromedin U on energy and glucose homeostasis. Endocrinology. 2011; 152(7):2644-54. DOI: 10.1210/en.2010-1463. View

Perez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro A, Garcia-Aranda M, De Las Rivas J . Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updat. 2020; 53:100718. DOI: 10.1016/j.drup.2020.100718. View

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

Sturm G, Finotello F, List M . Immunedeconv: An R Package for Unified Access to Computational Methods for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Data. Methods Mol Biol. 2020; 2120:223-232. DOI: 10.1007/978-1-0716-0327-7_16. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P . Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2024; 1(3):e36. PMC: 10989974. DOI: 10.1002/imt2.36. View

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

Liu C, Hu F, Xie G, Miao Y, Li X, Zeng Y . GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief Bioinform. 2022; 24(1). DOI: 10.1093/bib/bbac558. View

10.

Woan K, Miller J . Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside. Cancer Immunol Res. 2019; 7(11):1742-1747. PMC: 6830516. DOI: 10.1158/2326-6066.CIR-19-0404. View

11.

Guo L, Wang Y, Yang W, Wang C, Guo T, Yang J . Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis. Gastroenterology. 2023; 165(2):414-428.e7. DOI: 10.1053/j.gastro.2023.04.029. View

12.

Teng M, Ngiow S, Ribas A, Smyth M . Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015; 75(11):2139-45. PMC: 4452411. DOI: 10.1158/0008-5472.CAN-15-0255. View

13.

Li C, Liu B, Kang B, Liu Z, Liu Y, Chen C . SciBet as a portable and fast single cell type identifier. Nat Commun. 2020; 11(1):1818. PMC: 7156687. DOI: 10.1038/s41467-020-15523-2. View

14.

Sveen A, Kopetz S, Lothe R . Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2019; 17(1):11-32. PMC: 7577509. DOI: 10.1038/s41571-019-0241-1. View

15.

Gao Y, Zhou Y, Wei L, Feng Z, Chen Y, Liu P . Hsa_Circ_0066351 Acts as a Prognostic and Immunotherapeutic Biomarker in Colorectal Cancer. Front Immunol. 2022; 13:927811. PMC: 9667793. DOI: 10.3389/fimmu.2022.927811. View

16.

Lyu F, Han F, Ge C, Mao W, Chen L, Hu H . OmicStudio: A composable bioinformatics cloud platform with real-time feedback that can generate high-quality graphs for publication. Imeta. 2024; 2(1):e85. PMC: 10989813. DOI: 10.1002/imt2.85. View

17.

Hao C, Wu X, Zhou R, Zhang H, Zhou Y, Wang X . Downregulation of p66Shc can reduce oxidative stress and apoptosis in oxidative stress model of marginal cells of stria vascularis in Sprague Dawley rats. Drug Des Devel Ther. 2019; 13:3199-3206. PMC: 6751335. DOI: 10.2147/DDDT.S214918. View

18.

Howard A, Wang R, Pong S, Mellin T, Strack A, Guan X . Identification of receptors for neuromedin U and its role in feeding. Nature. 2000; 406(6791):70-4. DOI: 10.1038/35017610. View

19.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

20.

Souza-Fonseca-Guimaraes F, Cursons J, Huntington N . The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. Trends Immunol. 2019; 40(2):142-158. DOI: 10.1016/j.it.2018.12.003. View